Slingshot Insights

Catalyst

Slingshot members are tracking this event:

AbbVie commences Phase 3 trial of ABT-494 for rheumatoid arthritis, expected completion mid-2017

Source Link:: http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=251551&fid=14218269

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ABBV

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "In January 2016, AbbVie announced the commencement of a Phase 3 clinical trial program to study the use of AbbVie's once-daily formulation of ABT-494, its internally developed investigational selective Janus Kinase 1 (JAK-1) inhibitor, for the treatment of rheumatoid arthritis." The study is estimated to complete in June 2017.

https://www.clinical...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 07, 2017

Occurred Source:

https://news.abbvie.com/alert-topics/immunology/abbvies-upadacitinib-abt-494-meets-all-primary-and-ranked-secondary-endpoints-in-phase-3-study-in-rheumatoid-arthritis.htm

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Abt-494, Rheumatoid Arthritis